IP Library Patent Application 14426777
Patent Application
App. No. 14/426,777

Formulations Comprising Idebenone, N-Acetyl-S-Farnesyl-L-Cysteine and Ergothioneine and Uses Thereof

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/426,777
Abstract

Compositions that mitigate damage caused by environmental stressors are provided. The stressors include, but are not limited to, damage caused by ultra-violet radiation. The compositions comprise an effective amount of idebenone or a derivative thereof, N-acetyl-S-farnesyl-L-cysteine or a pharmaceutically acceptable salt or ester thereof and ergothioneine or a pharmaceutically acceptable salt or ester thereof. In some embodiments these compositions are applied topically to a person's skin.

Claims (19)

1 . A formulation comprising: idebenone or a derivative thereof, N-acetyl-S-farnesyl-L-cysteine or a pharmaceutically acceptable salt or ester thereof and ergothioneine or a pharmaceutically acceptable salt or ester thereof.

2 . The formulation of claim 1 , wherein

(a) the idebenone or the derivative thereof is present in an amount of 0.0001-5.0 wt. % based on the total weight of the formulation;

(b) the N-acetyl-S-farnesyl-L-cysteine or the pharmaceutically acceptable salt or ester thereof is present in an amount of 0.0001-10.0 wt. % based on the total weight of the formulation; and

(c) the ergothioneine or the pharmaceutically acceptable salt or ester thereof is present in an amount of 0.0001-10.0 wt. % based on the total weight of the formulation.

3 . The formulation of claim 2 , wherein the idebenone or the derivative thereof is:

4 . A method for preventing a skin change, said method comprising applying a topical preparation to the skin, the preparation comprising an effective amount of idebenone or a derivative thereof, N-acetyl-S-farnesyl-L-cysteine or a pharmaceutically acceptable salt or ester thereof and ergothioneine or a pharmaceutically acceptable salt or ester thereof.

5 . A method of inhibiting UV induction of pro-inflammatory cytokines, said method comprising administering a formulation of claim 1 to an organism, wherein said organism has been exposed to UV radiation.

6 . The method of claim 5 , wherein said administering is by topically applying the formulation to the organism.

7 . The method of claim 6 , wherein the formulation is applied to a region of skin of the organism.

8 . The method of claim 5 , wherein the cytokines comprise IL-6 or TNF-α or a combination thereof.

9 . A method for reducing sun burn cell formation, said method comprising administering an effective amount of a formulation of claim 1 to an organism, wherein said organism has been exposed to UV radiation.

10 . A method for treating inflammation comprising administering an effective amount of a formulation according to claim 1 to a person in need thereof.

11 . A method for repairing DNA damage comprising administering an effective amount of a formulation according to claim 1 to a person in need thereof.

12 . A method for treating human skin comprising topically applying to the human skin an effective amount of a composition comprising the formulation of claim 1 , wherein said treating comprises scavenging for free radicals.

13 . A method for treating human skin comprising topically applying to the human skin an effective amount of a composition comprising the formulation of claim 1 , wherein said treating comprises an anti-oxidant effect.

14 . The method according to claim 13 , wherein said anti-oxidant effect protects against skin aging.

15 . A method for treating human skin comprising topically applying to the human skin an effective amount of a composition comprising the formulation of claim 1 , wherein said treating mitigates against at least one of UV-induced pro-inflammatory cytokines and MMP production.

16 . The method according to claim 15 , wherein said treating mitigates against both of UV-induced pro-inflammatory cytokines and MMP production.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 18, 2020
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: CREATIVE NAIL DESIGN, INC.; ELIZABETH ARDEN, INC.; FD MANAGEMENT, INC.; REVLON CONSUMER PRODUCTS CORPORATION; ROUX LABORATORIES, INC.; SINFULCOLORS INC.
Reel/Frame 052694/0508 →
SECURITY INTEREST Recorded Aug 6, 2019
From: CREATIVE NAIL DESIGN, INC.; ELIZABETH ARDEN, INC.; FD MANAGEMENT, INC.; REVLON CONSUMER PRODUCTS CORPORATION; ROUX LABORATORIES, INC.; SINFULCOLORS INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 049969/0038 →
PATENT SECURITY AGREEMENT Recorded Oct 4, 2016
From: ELIZABETH ARDEN, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040219/0253 →
PATENT SECURITY AGREEMENT (TERM) Recorded Oct 4, 2016
From: ELIZABETH ARDEN, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 040220/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2015
From: FERNANDEZ, JOSE; PEREZ, EDUARDO; STOCK, MAXWELL; POPESCU, LAVINIA CODRUTA; FELIX-GONNOT, AURELIE NATHALIE; PELLEGRINO, ARTHUR JOSEPH
To: ELIZABETH ARDEN, INC.
Reel/Frame 035117/0622 →